Condition: Acute Liver Failure · Acute-On-Chronic Liver Failure · Sponsor: Beijing Continent Pharmaceutical Co, Ltd.
This study was a randomized, double-blind, placebo-controlled PhaseⅡ clinical trial . The primary objective of this study was to evaluate the safety of F573 for injection in patients with liver injury (drug-induced liver injury (DILI), chronic hepatitis B (CHB), intrahepatic cholestatic liver injury, etc.).
This description comes directly from the study's public registry record.
ling zhang, Dr · 13501209210 · zhangling@bjcontinent.com
junqi niu, Dr
Always discuss trial participation with your own doctor first.
| Beijing You 'an Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Qingyuan People's Hospital (Sixth Affiliated Hospital of Guangzhou Medical University) | Qingyuan, Guangdong, China | Recruiting |
| Shiyan City Taihe Hospital | Shiyan, Hubei, China | Recruiting |
| Hunan Medical College General Hospital (formerly Huaihua City First People's Hospital) | Huaihua, Hunan, China | Recruiting |
| Pingxiang Second People's Hospital | Pingxiang, Jiangxi P, China | Recruiting |
| First Hospital of Jilin University | Changchun, Jilin, China | Recruiting |
| The Affiliated Hospital of Binzhou Medical University | Binzhou, Shandong, China | Recruiting |
| Heze Municipal Hospital | Heze, Shandong, China | Recruiting |
| Shanxi Bethune Hospital | Taiyuan, Shanxi, China | Recruiting |
| Affiliated Hospital of Southwest Medical University | Luzhou, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05689645